Avidity Biosciences Net Income
| RNA Stock | USD 72.87 0.04 0.05% |
As of the 13th of February 2026, Avidity Biosciences shows the Risk Adjusted Performance of 0.1807, coefficient of variation of 399.62, and Mean Deviation of 0.1673. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Avidity Biosciences, as well as the relationship between them.
Avidity Biosciences Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 452.3064 | Revenue | Earnings Share (4.19) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -290.1 M | -275.6 M | |
| Net Loss | -156.6 M | -148.8 M | |
| Net Loss | -290.1 M | -275.6 M | |
| Net Loss | (3.32) | (3.49) | |
| Net Income Per E B T | 0.96 | 0.85 |
Avidity | Net Income | Build AI portfolio with Avidity Stock |
Analyzing Avidity Biosciences's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Avidity Biosciences's current valuation and future prospects.
Latest Avidity Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Avidity Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Avidity Biosciences financial statement analysis. It represents the amount of money remaining after all of Avidity Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Avidity Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avidity Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (322.3 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Avidity Net Income Regression Statistics
| Arithmetic Mean | (91,925,354) | |
| Coefficient Of Variation | (125.08) | |
| Mean Deviation | 98,241,987 | |
| Median | (11,934,000) | |
| Standard Deviation | 114,981,388 | |
| Sample Variance | 13220.7T | |
| Range | 310.4M | |
| R-Value | (0.85) | |
| Mean Square Error | 3797.1T | |
| R-Squared | 0.73 | |
| Significance | 0.000012 | |
| Slope | (19,464,344) | |
| Total Sum of Squares | 211531.5T |
Avidity Net Income History
Other Fundumenentals of Avidity Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Avidity Biosciences Net Income component correlations
Avidity Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Avidity Biosciences is extremely important. It helps to project a fair market value of Avidity Stock properly, considering its historical fundamentals such as Net Income. Since Avidity Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Avidity Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Avidity Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. Anticipated expansion of Avidity directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Avidity Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.19) | Revenue Per Share | Quarterly Revenue Growth 4.34 | Return On Assets | Return On Equity |
Understanding Avidity Biosciences requires distinguishing between market price and book value, where the latter reflects Avidity's accounting equity. The concept of intrinsic value - what Avidity Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Avidity Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Avidity Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Avidity Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Avidity Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Avidity Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Avidity Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Avidity Biosciences.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Avidity Biosciences on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Avidity Biosciences or generate 0.0% return on investment in Avidity Biosciences over 90 days. Avidity Biosciences is related to or competes with Jazz Pharmaceuticals, Madrigal Pharmaceuticals, Caris Life, Moderna, Abivax SA, Cytokinetics, and Nuvalent. Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies More
Avidity Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Avidity Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Avidity Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 0.2031 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 1.75 | |||
| Value At Risk | (0.29) | |||
| Potential Upside | 0.3757 |
Avidity Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avidity Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Avidity Biosciences' standard deviation. In reality, there are many statistical measures that can use Avidity Biosciences historical prices to predict the future Avidity Biosciences' volatility.| Risk Adjusted Performance | 0.1807 | |||
| Jensen Alpha | 0.0482 | |||
| Total Risk Alpha | 0.0355 | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | 0.5079 |
Avidity Biosciences February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1807 | |||
| Market Risk Adjusted Performance | 0.5179 | |||
| Mean Deviation | 0.1673 | |||
| Downside Deviation | 0.2031 | |||
| Coefficient Of Variation | 399.62 | |||
| Standard Deviation | 0.2585 | |||
| Variance | 0.0668 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | 0.0482 | |||
| Total Risk Alpha | 0.0355 | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | 0.5079 | |||
| Maximum Drawdown | 1.75 | |||
| Value At Risk | (0.29) | |||
| Potential Upside | 0.3757 | |||
| Downside Variance | 0.0412 | |||
| Semi Variance | (0.04) | |||
| Expected Short fall | (0.21) | |||
| Skewness | 1.65 | |||
| Kurtosis | 7.04 |
Avidity Biosciences Backtested Returns
At this point, Avidity Biosciences is very steady. Avidity Biosciences secures Sharpe Ratio (or Efficiency) of 0.23, which signifies that the company had a 0.23 % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for Avidity Biosciences, which you can use to evaluate the volatility of the firm. Please confirm Avidity Biosciences' Mean Deviation of 0.1673, risk adjusted performance of 0.1807, and Coefficient Of Variation of 399.62 to double-check if the risk estimate we provide is consistent with the expected return of 0.0503%. Avidity Biosciences has a performance score of 18 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.11, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Avidity Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Avidity Biosciences is expected to be smaller as well. Avidity Biosciences right now shows a risk of 0.22%. Please confirm Avidity Biosciences downside variance, and the relationship between the treynor ratio and kurtosis , to decide if Avidity Biosciences will be following its price patterns.
Auto-correlation | 0.85 |
Very good predictability
Avidity Biosciences has very good predictability. Overlapping area represents the amount of predictability between Avidity Biosciences time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Avidity Biosciences price movement. The serial correlation of 0.85 indicates that around 85.0% of current Avidity Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.85 | |
| Spearman Rank Test | 0.83 | |
| Residual Average | 0.0 | |
| Price Variance | 0.06 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Avidity Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Avidity Biosciences reported net income of (322.3 Million). This is 194.44% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 156.45% higher than that of the company.
Avidity Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avidity Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avidity Biosciences could also be used in its relative valuation, which is a method of valuing Avidity Biosciences by comparing valuation metrics of similar companies.Avidity Biosciences is currently under evaluation in net income category among its peers.
Avidity Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Avidity Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Avidity Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Avidity Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Avidity Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Avidity Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Avidity Biosciences' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 2.8 M | Bank Of America Corp | 2025-06-30 | 1.8 M | Orbimed Advisors, Llc | 2025-06-30 | 1.8 M | Casdin Capital, Llc | 2025-06-30 | 1.8 M | Polar Capital Holdings Plc | 2025-06-30 | 1.8 M | Adage Capital Partners Gp Llc | 2025-06-30 | 1.5 M | Goldman Sachs Group Inc | 2025-06-30 | 1.1 M | Siren, L.l.c. | 2025-06-30 | 1.1 M | Charles Schwab Investment Management Inc | 2025-06-30 | 1 M | Fmr Inc | 2025-06-30 | 16.2 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 10.8 M |
Avidity Fundamentals
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (15.13) % | ||||
| Current Valuation | 9.44 B | ||||
| Shares Outstanding | 154.48 M | ||||
| Shares Owned By Insiders | 3.72 % | ||||
| Shares Owned By Institutions | 96.28 % | ||||
| Number Of Shares Shorted | 8.75 M | ||||
| Price To Earning | (12.91) X | ||||
| Price To Book | 5.97 X | ||||
| Price To Sales | 539.73 X | ||||
| Revenue | 10.9 M | ||||
| Gross Profit | (467.32 M) | ||||
| EBITDA | (376.16 M) | ||||
| Net Income | (322.3 M) | ||||
| Cash And Equivalents | 398.22 M | ||||
| Cash Per Share | 7.64 X | ||||
| Total Debt | 6.8 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.00 X | ||||
| Book Value Per Share | 12.85 X | ||||
| Cash Flow From Operations | (300.87 M) | ||||
| Short Ratio | 5.36 X | ||||
| Earnings Per Share | (4.19) X | ||||
| Target Price | 74.64 | ||||
| Number Of Employees | 391 | ||||
| Beta | 0.93 | ||||
| Market Capitalization | 11.26 B | ||||
| Total Asset | 1.56 B | ||||
| Retained Earnings | (893.07 M) | ||||
| Working Capital | 1.44 B | ||||
| Current Asset | 50.65 M | ||||
| Current Liabilities | 16.97 M | ||||
| Net Asset | 1.56 B |
About Avidity Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avidity Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avidity Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avidity Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Avidity Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avidity Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avidity Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avidity Biosciences Stock:Check out For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. Anticipated expansion of Avidity directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Avidity Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.19) | Revenue Per Share | Quarterly Revenue Growth 4.34 | Return On Assets | Return On Equity |
Understanding Avidity Biosciences requires distinguishing between market price and book value, where the latter reflects Avidity's accounting equity. The concept of intrinsic value - what Avidity Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Avidity Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Avidity Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Avidity Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Avidity Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.